# Galderma to Present Eight Scientific Abstracts and Body-Indication Data at AMWC Dubai 2026 > Galderma will present eight scientific abstracts at AMWC Dubai 2026, covering Relfydess, Sculptra and Restylane plus a survey of over 4,300 women. - Published: 2026-10-21T05:39:53+00:00 - Section: Research & Clinical Trials - Author: News Desk - URL: https://newsforagent.com/news/2026-10-21/galderma-amwc-dubai-2026-abstracts - Source: [Business Wire](https://www.businesswire.com/news/home/20261020743872/en/) ## Key takeaways - Galderma will present eight scientific abstracts, a symposium and six Meet-the-Expert sessions at AMWC Dubai 2026, held October 21-23, 2026. - Sculptra data follows its approval in the UAE expanding its clinical application from the face to the gluteal area, posterior thighs and décolletage. - A global survey of over 4,300 women across nine countries examined menopause-related skin changes, with 80% of patients seeking information on Sculptra. Galderma will present eight scientific abstracts, a symposium and six Meet-the-Expert sessions at the Aesthetic & Anti-Aging Medicine World Congress in Dubai, United Arab Emirates, from October 21-23, 2026, the company said. The presentations cover Relfydess, Sculptra and the Restylane range. The announcement was distributed by [Business Wire](https://www.businesswire.com/news/home/20261020743872/en/). ## Galderma's Eight Abstracts at AMWC Dubai [Galderma](https://akta.pro/company-profiles/00000vk/galderma) said the data span face and body indications. Sculptra, described as the first proven regenerative biostimulator, will be presented following its approval in the UAE expanding its current clinical application for the face to include the gluteal area, posterior thighs and décolletage. Guidance from an international consensus panel of 11 experts will outline combination strategies across approved body indications, highlighting complementary benefits of Sculptra and Restylane Skinboosters in the posterior thighs and gluteal area. Data from Restylane Shaype, described as the first-and-only hyaluronic acid shaper developed with NASHA-HD technology, along with expanded indications for Restylane Lyft and Restylane Volyme, are being presented with clinical evidence in the chin, jawline, temples and lower face. Across four studies, Restylane delivered well-tolerated, effective and long-lasting aesthetic improvements in multiple facial regions, consistently achieving high responder rates and high subject satisfaction. Data evaluating Restylane Skinboosters for correction of moderate-to-severe wrinkles in the décolletage will also be shared. A dedicated symposium on the AART of Body will take place Thursday, October 22, from 11:00 AM to 1:00 PM GST in Baniyas ballroom 1. Galderma will also share insights from a global survey of over 4,300 women across nine countries on menopause-related skin changes, in which biostimulators and dermal fillers were the most frequently considered treatments, with 80% of patients looking for information on Sculptra and 75% for information on the Restylane range. ## Galderma's Injectable Aesthetics Revenue According to akta.pro [company records](https://akta.pro/company-data), Galderma's Injectable Aesthetics business recorded $648 million in Q1 2026 revenue, with 13.1% growth. The company's Q1 2026 net sales were $1.473 billion, representing 25.5% year-on-year growth at constant currency. Galderma is a global pure-play dermatology company selling injectable aesthetics, therapeutic dermatology drugs and consumer skincare across more than 90 countries, and it was founded in 1981 with headquarters in Lausanne, Switzerland. ## Galderma's Recent Restylane and Sculptra Milestones On October 6, 2026, Galderma marked 30 years since Restylane launched as the first hyaluronic acid injectable, with new approvals including Restylane Shaype for chin enhancement in the EU, a new syringe in the EU, the U.S. and Canada, and Restylane Volyme for temple hollowing in the U.S., FinanzNachrichten.de reported. On October 1, 2026, Le Monde.fr reported that Sculptra, a collagen stimulator, is marketed to counter Ozempic face, a facial sagging from rapid weight loss, at 500 euros per syringe. On October 13, 2026, Yahoo reported that Galderma agreed to buy ZO Skin Health for around $1.5 billion, with a deal announcement expected in coming days. ## Galderma's AMWC Dubai Symposium Timing The AMWC Dubai 2026 congress runs from October 21-23, 2026, and Galderma's symposium is scheduled for October 22, 2026, from 11:00 AM to 1:00 PM GST in Baniyas ballroom 1. ## Companies in this story - [Galderma company profile](https://akta.pro/company-profiles/00000vk/galderma) · website: http://www.galderma.com --- News for Agent · https://newsforagent.com/llms.txt